Innate Pharma SA
PAR:IPH

Watchlist Manager
Innate Pharma SA Logo
Innate Pharma SA
PAR:IPH
Watchlist
Price: 1.946 EUR 1.14%
Market Cap: 157.5m EUR
Have any thoughts about
Innate Pharma SA?
Write Note

Innate Pharma SA
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Innate Pharma SA
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Innate Pharma SA
PAR:IPH
Interest Income Expense
€2.5m
CAGR 3-Years
N/A
CAGR 5-Years
89%
CAGR 10-Years
31%
Valneva SE
PAR:VLA
Interest Income Expense
-€35.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
G
Genfit SA
PAR:GNFT
Interest Income Expense
-€2.6m
CAGR 3-Years
44%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Interest Income Expense
-€8.2m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
Interest Income Expense
-€2.4m
CAGR 3-Years
-51%
CAGR 5-Years
-24%
CAGR 10-Years
-25%
OSE Immunotherapeutics SA
PAR:OSE
Interest Income Expense
-€4.4m
CAGR 3-Years
-139%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Innate Pharma SA
Glance View

Market Cap
157.5m EUR
Industry
Biotechnology

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. The company is headquartered in Marseille, Paca and currently employs 215 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The firm works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.

IPH Intrinsic Value
5.098 EUR
Undervaluation 62%
Intrinsic Value
Price

See Also

What is Innate Pharma SA's Interest Income Expense?
Interest Income Expense
2.5m EUR

Based on the financial report for Jun 30, 2024, Innate Pharma SA's Interest Income Expense amounts to 2.5m EUR.

What is Innate Pharma SA's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
31%

Over the last year, the Interest Income Expense growth was 22%.

Back to Top